Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies

G Cazzaniga; P de Lorenzo; J Alten; S Röttgers; J Hancock; V Saha; Vincent van der Velden; MG Valsecchi; A Biondi

doi:10.3324/haematol.2017.176917

Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies

G Cazzaniga, P de Lorenzo, J Alten, S Röttgers, J Hancock, V Saha, Vincent van der Velden, MG Valsecchi, A Biondi

Immunology

Research output: Contribution to journal › Article › Academic › peer-review

36 Citations (Scopus)

Original language	Undefined/Unknown
Pages (from-to)	107-115
Number of pages	9
Journal	Haematologica
Volume	103
Issue number	1
DOIs	https://doi.org/10.3324/haematol.2017.176917
Publication status	Published - 2018

Access to Document

10.3324/haematol.2017.176917

Cite this

Cazzaniga, G., de Lorenzo, P., Alten, J., Röttgers, S., Hancock, J., Saha, V., van der Velden, V., Valsecchi, MG., & Biondi, A. (2018). Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies. Haematologica, 103(1), 107-115. https://doi.org/10.3324/haematol.2017.176917

Cazzaniga, G ; de Lorenzo, P ; Alten, J ; Röttgers, S ; Hancock, J ; Saha, V ; van der Velden, Vincent ; Valsecchi, MG ; Biondi, A. / Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies. In: Haematologica. 2018 ; Vol. 103, No. 1. pp. 107-115.

@article{682165d6bf164188a748876de7951c83,

title = "Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies",

author = "G Cazzaniga and {de Lorenzo}, P and J Alten and S R{\"o}ttgers and J Hancock and V Saha and {van der Velden}, Vincent and MG Valsecchi and A Biondi",

year = "2018",

doi = "10.3324/haematol.2017.176917",

language = "Undefined/Unknown",

volume = "103",

pages = "107--115",

journal = "Haematologica",

issn = "0390-6078",

publisher = "Ferrata Storti Foundation",

number = "1",

}

Cazzaniga, G, de Lorenzo, P, Alten, J, Röttgers, S, Hancock, J, Saha, V, van der Velden, V, Valsecchi, MG & Biondi, A 2018, 'Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies', Haematologica, vol. 103, no. 1, pp. 107-115. https://doi.org/10.3324/haematol.2017.176917

Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies. / Cazzaniga, G; de Lorenzo, P; Alten, J; Röttgers, S; Hancock, J; Saha, V; van der Velden, Vincent; Valsecchi, MG; Biondi, A.

In: Haematologica, Vol. 103, No. 1, 2018, p. 107-115.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies

AU - Cazzaniga, G

AU - de Lorenzo, P

AU - Alten, J

AU - Röttgers, S

AU - Hancock, J

AU - Saha, V

AU - van der Velden, Vincent

AU - Valsecchi, MG

AU - Biondi, A

PY - 2018

Y1 - 2018

U2 - 10.3324/haematol.2017.176917

DO - 10.3324/haematol.2017.176917

M3 - Article

VL - 103

SP - 107

EP - 115

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 1

ER -

Cazzaniga G, de Lorenzo P, Alten J, Röttgers S, Hancock J, Saha V et al. Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies. Haematologica. 2018;103(1):107-115. https://doi.org/10.3324/haematol.2017.176917